

Development and Validation of Reverse Phase High Performance Liquid Chromatographic Method for Estimation of Brimonidine Tartrate

Umesh D. Laddha*, Savita S. Mandan, Archana V. Nerpagar, Sanjay J. Surana

R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule-425405, (MS), India.

ABSTRACT

Brimonidine Tartrate is used for the topical treatment of glaucoma to reduce intra ocular pressure (IOP). It can be used either in combination with other IOP lowering drugs or alone. So many methods have been developed for the determination of Brimonidine Tartrate in combination but there is no method for estimation of drug alone. For estimation of Brimonidine Tartrate in bulk drug and ophthalmic dosage form, reverse phase high performance liquid chromatographic method was developed and validated as per ICH guidelines Q2R(1). Chromatography was performed on Kromasil C-18 column (250 mm X 4.6 mm i.d., 5 µm particle size). Mobile phase was citric acid monohydrate buffer: water: methanol (30:50:20 v/v/v). The pH of buffer was maintained to 3 by using triethylamine. The flow rate was 1.0 ml/min. Elute was detected at 246 nm and it effectively separated at retention Time of 5.96 min. Method was validated for various parameters like calibration curve (linearity), accuracy, specificity, robustness, precision etc. A linear response was observed over the concentration range 40-80 µg/ml for Brimonidine Tartrate. The LOD and LOQ was 1.47 and 4.47 µg/ml respectively. Thus the proposed RP-HPLC method is rapid, accurate, precise and economically viable for the estimation of Brimonidine Tartrate in pure form as well as in ophthalmic formulation.

Keywords: Brimonidine tartrate, ophthalmic formulation, reversed phase-HPLC, validation

Received 12 May 2016

Received in revised form 07 June 2016

Accepted 15 July 2016

*Address of Correspondence:

Mr. Umesh D. Laddha,

Assistant Professor, Department of Pharmaceutics, R. C. Patel, Institute of Pharmaceutical Education and Research, Shirpur, Dhule, Maharashtra, India.

Email: umeshladdha698@gmail.com

1. INTRODUCTION

Glaucoma is the second most leading cause of world's blindness characterized by irreversible damage to the ganglionic cells and the optic nerve [1-3]. Presently, treatment of glaucoma focuses mainly on lowering of IOP. On the basis of which several classes of topical IOP lowering drugs have been developed. It includes beta blocker, prostaglandin analogue (PGA), alpha-adrenoceptor agonist (AA) and topical carbonic anhydrase inhibitors (CAI's) [4].

Brimonidine Tartrate is used topically in the treatment of open-angle glaucoma or ocular hypertension. It is selective alpha-adrenoceptor agonist which has a dual mechanism of action; it reduces aqueous humor production thereby reducing intraocular pressure and increases uveoscleral outflow [5-7]. Brimonidine Tartrate is enlisted in Martindale and Merck index [8,

9]. Chemically it is 5-bromo-6-(2 imidazolidinylideneamino) quinoxaline L-tartrate [10].

Literature survey revealed that various HPLC methods have been developed for simultaneous estimation of Brimonidine Tartrate in combination of other drugs. But there is no method for estimation of drug alone in pharmaceutical formulation [7,10-13].

While few HPTLC, HPLC, LC-MS, HILIC, TLC-densitometry methods reported for the estimation of Brimonidine Tartrate in blood serum and in ocular fluids [14-17].

The aim of study is to develop and validate simple, specific, sensitive, accurate and precise HPLC method for determination of Brimonidine Tartrate in ophthalmic formulation as per International Conference on Harmonization (ICH) guidelines [18, 19].




Figure 1: Structure of Brimonidine Tartrate

2. Material and Methods

2.1 Apparatus

A Shimadzu RP-HPLC instrument (LC -20 AD as per CFR 21) equipped with an photodiode array detector, manual injector with 20 μ l loop, and Kromasil C18 column (250 mm \times 4.6 mm id, 5 μ m particle size) and LC- solution software was used. Contech CB-50 analytical balance and ultra sonic cleaner (Spectralab, UCB-40) were used during the study.

2.2 Reagents and materials

Brimonidine Tartrate was received as gift sample from Cipla Ltd., (Mumbai, Maharashtra). HPLC grade methanol (Qualigens), citric acid monohydrate buffer was of AR grade and water for RP-HPLC was prepared by double glass distillation and filtered through nylon membrane filter 0.45 μ m.

2.3 Chromatographic conditions

Kromasil C18 Column (250 mm \times 4.6 mm id, 5 μ m particle size) was used at ambient temperature. The mobile phase consisted of citric acid monohydrate buffer:water: methanol (30: 50:20 v/v/v) and pH 3 was maintained by triethylamine. Flow rate was 1.0 ml/min. The mobile phase was filtered through a 0.45 μ m membrane filter and degassed before used. The elution was monitored at 246 nm and injection volume was 20 μ l.

2.4 Preparation of solutions

2.4.1 Citric Acid Buffer

Accurately weighed Citric acid monohydrate (1.05 gm) was transferred to a beaker (500 ml) and dissolved in double distilled water (500 ml).

2.4.2 Preparation of Standard Stock Solution

Standard stock solution of Brimonidine Tartrate was prepared by dissolving 10 mg of drug in 10 ml of methanol to get the concentration of 1 mg/ml from which 1 ml

was further diluted to 10 ml with methanol to obtain a working standard having a concentration of 100 μ g/ μ l.

2.5 Determination of wavelength of maximum absorbance

The standard solutions of Brimonidine Tartrate were scanned in the range of 200-400 nm against buffer solution as a blank. Brimonidine Tartrate showed maximum absorbance at 246 nm. So the wavelength selected for the determination of Brimonidine Tartrate was 246 nm.

2.6 Method Validation[19]

2.6.1 Calibration curve (Linearity)

Calibration curve was plotted over concentration range of 40-80 μ g/ml for Brimonidine Tartrate. Accurately measured standard stock solution of Brimonidine Tartrate (4, 5, 6, 7 and 8 ml) was transferred to a series of 10 ml volumetric flask and volume in each flask was adjusted 10 ml with mobile phase. Resulting solution were injected into the column and the peak area obtained at flow rate of 1.0 ml per minute for Brimonidine Tartrate. Calibration curve was constructed for Brimonidine Tartrate by plotting peak area versus concentration at 246 nm. Each reading was average of three determinations.

2.6.2 Accuracy (% Recovery)

To check the accuracy of the method, recovery studies were carried out by addition of formulation to pre-analyzed sample solution at three different levels 80, 100 and 120 %. Chromatogram was obtained and the peak areas were noted. At each level of the amount, three determinations were carried out.

2.6.3 Limit of Detection and Limit of Quantification

The limit of detection (LOD) and limit of Quantification (LOQ) for Brimonidine Tartrate was derived by calculating signal-to-noise ratio (S/N, i.e. 3.3 for LOD and 10 for LOQ) and using following equation as per International Conference on Harmonization (ICH) guidelines.

$$\text{LOD} = 3.3 \times \sigma/S$$

$$\text{LOQ} = 10 \times \sigma/S$$

Where σ = the standard deviation of the responses and

S = Slope of calibration curve.

2.6.4 Specificity and System Suitability

Specificity is the ability to assess unequivocally the analyte in the presence of components, which may be expected to be present. Typically these might include impurities, degradants, matrix etc. One blank and one standard preparation was injected and chromatograms were recorded which is further calculated for system suitability parameters.

2.6.5 Robustness

Robustness studies were carried out by examining the effect of small, deliberate variation of the analytical conditions on the peak areas of the drug. Factors varied were volume of mobile phase (± 3 ml), wavelength (± 2 nm) and flow rate (± 0.2 ml/min). One factor at a time was changed to study the effect.

2.6.6 Intra-day and Inter-day precision

The intra-day precision was determined by analyzing standard solution of Brimonidine Tartrate at 60 μ g/ml concentration for six replicates on the same day while inter-day precision was determined by analysing corresponding standard on two different days over a period of one week.

3. Result and discussion

To optimize the RP-HPLC parameters, several mobile phase compositions were tried. A satisfactory separation and good peak symmetry was found in a mixture of citric acid monohydrate buffer pH 3, methanol and water (30:20:50) at 1.0 ml/min flow rate. As it was shown in (Figure 2), the optimum wavelength for detection was set at 246 nm at which much better detector responses for Brimonidine Tartrate was obtained. The retention time was 5.962 min as reported in (Figure 3).




Figure 2: Maximum detection wavelength of Brimonidine Tartrate




Figure 3: Typical RP-HPLC Chromatogram Brimonidine Tartrate (40 μ g /ml) with corresponding retention time

Chromatographic conditions are outlined in (Table 1). The calibration graph for Brimonidine Tartrate was constructed by plotting the peak area versus their corresponding concentrations; good linearity was found over the range 40-80 μ g/ml. The calibration graph is shown in (Figure 4).

Table 1: Chromatographic conditions

Mobile Phase	0.01 Mol/L Citric acid monohydrate: Methanol : Water (30:20:50) pH 3 maintained by using triethylamine
Column	Kromasil – C 18 Column (250 mm \times 6.5 mm \times 5 μ m)
Flow Rate	1 ml/min
Detection Wavelength	246 nm
Injection Volume	20 μ l
Run Time	10 Minutes
Retention Time	5.96 mins




Figure 4: Calibration Curve of Brimonidine Tartrate

The proposed method has been applied to the assay of Brimonidine Tartrate in pharmaceutical dosage form. The results obtained indicate the additives present do not interfere with analysis of the studied formulation. System suitability test parameters for Brimonidine Tartrate for the RP-HPLC method are reported in (Table 2). The optical and regression characteristics and validation parameters are reported in (Table 3). Data of recovery study is shown in (Table 4). The robustness study is reported in (Table 5).

Table 2: System suitability testing of the HPLC method

System suitability Parameters	Observation	Acceptance Criteria
Peak Area	3419885	-
Tailing Factor	1.49	Not more than 2
Column Efficiency	5861	Not less than 2500
% R.S.D.	0.7425	Not more than 2

Table 3: The optical and regression characteristics and validation parameters of HPLC Method for analysis of Brimonidine tartrate

Parameter	Observation
Calibration range	40-80 µg/ml
Detection limit	1.477 µg/ml
Quantitation limit	4.476 µg/ml
Slope	85830
Intercept	17081
Correlation coefficient	0.999
Intraday RSD, %	0.7425
Interday RSD, %	Day 1 -0.7425 Day 2- 0.4202

Table 4: Data of recovery study for Brimonidine Tartrate by HPLC method

Amount taken (µg/ml)	Amount added (µg/ml)	Amount found	% Recovery
25	20	45.17	100.39
25	25	49.48	98.96
25	30	54.18	98.52

Table 5: Data of robustness study for Brimonidine Tartrate by HPLC method

Experiment	% RSD	Theoretical plates for Brimonidine peak	Tailing factor for Brimonidine peak
(+) Wavelength	0.244	5713	1.50
(-) Wavelength	0.167	5992	1.49
(+) Flow rate	0.549	5760	1.40
(-) Flow rate	1.300	6091	1.61
(+) Mobile phase volume	0.303	7065	1.46
(-) Mobile phase volume	0.653	5041	1.51

5.0 CONCLUSION

Reverse phase HPLC method was developed and validated as per ICH norms. Developed method is rapid, economic, accurate and precise for quantitative estimation of Brimonidine Tartrate in bulk and formulations.

REFERENCES

1. Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL. Intraocular pressure lowering effect of commonly used fixed combination drug with Timolol: A systematic review and meta-analysis. PLOS ONE 2011; 7:1-11.
2. Singh V, Bushetti SS, Raju SA, Ahmad R, Singh M. Glaucoma: A treatment by hydrogel. An Int. J. of Pharm Sci 2011;2:174-183.
3. Bhalerao AV, Singh SS. *In situ* gelling ophthalmic drug delivery system for glaucoma. Int J of Pharm and Bio Sci 2011;2:7-14.
4. Valk R, Webers CA, Schouten JS, Zeegers MP. Intraocular pressure-lowering effect of all commonly used glaucoma drugs: a meta analysis of randomized clinical trials. Ophthalmol 2005;112:1177-85.
5. Desai HH, Captain AD. Three simple validated UV spectrophotometric methods for the simultaneous estimation of timolol maleate and brimonidine tartrate and their comparison using ANOVA. Int J of Pharm Res & Analysis 2014;4(3):168-177.
6. Popaniya HS, Patel HM. Simultaneous determination of brimonidine Tartrate and timolol maleate in combined pharmaceutical dosage form using two different green spectrophotometric methods. World J of Pharm And Pharm Sci 2014; 3(3): 1330-1340.
7. Elshanawane AA, Abdelaziz LM, Mohram MS, Hafez HM. Development and Validation of HPLC Method for Simultaneous Estimation of brimonidine tartrate and timololmaleate in bulk and pharmaceutical dosage form. J Chromatograph SeparatTechniq 2014; 5: 1-5.
8. The Merck Index. 13th ed. Whitehouse Station, NJ: Merck Research Laboratories Division of Merck and Co., Inc; 2006. 225.
9. Sweetman, S. C. Martindale, the complete drug reference. 35th edition. London: Pharmaceutical press; 2005. 1012-1013.
10. Hafez HM, Elshanawane AA, Abdelaziz LM, Mohram MS. Development and validation of HPLC method for simultaneous estimation of brimonidine tartrate and timolol maleate in bulk and pharmaceutical dosage form. 2014; 6(4): 398-407.
11. Phogat A., Kumar M., Mahadevan N. Simultaneous estimation of Brimonidine Tartrate and Timolol Maleate in Nanoparticles Formulation by RP-HPLC. Int J of Recent Adv in Pharm Res 2011;3:31-36.
12. Sethi P. D. High performance liquid chromatography, Quantitative analysis of pharmaceutical formulation. 1st edition. 2001. 38-70.
13. Vinayaka DG, ShettySA, Manzoor A, Anil Kumar SM, SiddalingaSwamy MS. RP-HPLC method development and validation for simultaneous estimation of brimonidine tartrate and timolol maleate in combined ophthalmic dosage form. World J of Pharm and Pharm Sci 2014; 4 (1): 1019-1029.
14. Mehta SK, Maheshwari DG. Analytical method development and validation for simultaneous estimation of timolol maleate and brimonidine tartrate in bulk and marketed ophthalmic formulation. J of Pharm Sci and Biosci Res 2014; 4 (6): 351-356.
15. Jiang S, Chappa A, Proksch J. A rapid and sensitive LC/MS/MS assay for quantitation of brimonidine in ocular fluid and tissue. J Chromatogr B AnalytTechnol Biomed Life Sci 2009;3:107-114.
16. SonanisMC, Rajput AP. Development and validation of a new stability indicating analytical method for the determination of related components of brimonidine tartrate in drug substances and drug product using UPLC. Int J of Pharm and Pharm Sci 2011; 3 (1), 145-150.
17. Jain PS, Khatal RN, Jivani HN, Surana SJ. Development and Validation of TLC-densitometry Method for simultaneous estimation of brimonidine tartrate and Timolol maleate in bulk and pharmaceutical dosage form. J Chromatograph SeparatTechniq 2011; 2 (3): 1-5.
18. Laddha UD, Barse RK, Zilpelwar RV, Tagalpallewar AA. Development and validation of stability indicating reverse phase high performance liquid chromatography method for timolol maleate. Int J PharmTech Res 2014; 6:1429-1435
19. ICH Harmonised Tripartite Guideline Validation of Analytical Procedures: Text and Methodology Q2 (R1) 2005.